Renal-Cell Carcinoma

Surgery is typically the gold standard for patients with biopsy-proven, clear cell, renal cell carcinoma with no evidence of metastatic disease, said Eric Jonasch, MD, in a session during the National Comprehensive Cancer Network Annual Conference. In this setting, there is probably not a role for systemic neoadjuvant treatment, as response rates of 15% to 45% have been recorded with axitinib (Inlyta), sunitinib (Sutent), and other tyrosine kinase inhibitors. Read More ›

The decision to use adjuvant therapies in patients with renal-cell carcinoma (RCC) should be based on risk, patient goals, and shared decision-making. This topic was explored in a presentation by Matthew Zibelman, MD, Associate Professor, Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA, at the 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium. Read More ›

Adjuvant pembrolizumab (Key­truda) continued to provide a disease-free survival (DFS) benefit in patients with renal-cell carcinoma (RCC) at intermediate-high or high risk of recurrence after nephrectomy, according to 30-month follow-up data from the KEYNOTE-564 trial presented at the 2022 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium. Read More ›


In a retrospective study, active therapy conferred a survival benefit versus BSC for patients who have disease progression on both nivolumab and cabozantinib. Read More ›

Since the approval of dual immune checkpoint inhibition, real-world treatment patterns have evolved. Read More ›

Blood flow measured by dynamic contrast-enhanced computed tomography can predict survival with antiangiogenic treatment. Read More ›


In a retrospective study, lenvatinib with or without everolimus resulted in antitumor activity in patients who had received previous tyrosine kinase inhibitors and immunotherapy. Read More ›

Rechallenge with nivolumab after first-line immune checkpoint inhibition has moderate antitumor activity and acceptable tolerability. Read More ›

Page 1 of 3


Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: